A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

Clinical trial NCT07510594 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07510594
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Large-Cell Neuroendocrine Carcinoma of the Lung Extrapulmonary Neuroendocrine Carcinoma

Start date: 2026-05-01
Primary completion: 2026-12-31
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.